<!DOCTYPE html>
<!-- Created with iSpring --><!-- 2560 1921 -->
<html><head><meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=1"/><meta name="format-detection" content="telephone=no"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="black"/><meta http-equiv="X-UA-Compatible" content="IE=edge"/><title>seebri_en_3_2_2_test</title><link rel="apple-touch-icon-precomposed" href="data/images/apple-touch-icon.png"/><link rel="shortcut icon" type="image/ico" href="data/images/favicon.ico"/><script src="data/player.js"></script><style>#spr3_48105 * {-webkit-transform-origin:0 0; -moz-transform-origin:0 0; -o-transform-origin:0 0; -ms-transform-origin:0 0; transform-origin:0 0;}#spr63_48105 {position:relative; -webkit-tap-highlight-color:rgba(0,0,0,0); -webkit-user-select:none; -moz-user-select:none; -webkit-touch-callout:none; -webkit-user-drag:none;}#spr63_48105 * {position:absolute;}body {background-color:#c0c0c0;}#spr0_48105,#spr4_48105,#spr14_48105,#svg2_48105,#spr20_48105,#spr41_48105,#svg14_48105,#spr45_48105,#spr46_48105,#spr47_48105,#spr48_48105,#spr49_48105,#spr50_48105,#spr53_48105,#spr54_48105,#spr55_48105,#spr56_48105 {display:none;}#spr2_48105,#spr3_48105 {clip:rect(0px,2560px,1921px,0px);}#spr3_48105 a img {border:0;}#spr3_48105 a {text-decoration:none; cursor:pointer;}</style></head><body><div id="spr0_48105"><div id="spr1_48105"><div id="spr2_48105" class="kern"><img id="img55_48105" src="data/images/img49.jpg" width="2560px" height="1921px" alt="" style="left:0px;top:0px;"/></div><div id="spr3_48105" class="kern"><div id="spr4_48105" style="left:-5.391px;top:0.26px;"><img id="img0_48105" src="data/images/img0.jpg" width="2560" height="1920" alt="C:\College\Dropbox\Launchpad (2)\Seebri\PowerPoint Seebri\3_2_2 popup.jpg" style="top:0.24px;"/></div><div id="spr5_48105" style="left:1651px;top:1486px;"><img id="img1_48105" src="data/images/img1.png" width="97" height="33" alt="Day 21"/></div><div id="spr6_48105" style="left:865px;top:1486px;"><img id="img2_48105" src="data/images/img2.png" width="78" height="33" alt="Day 1"/></div><div id="spr7_48105" style="left:1033.077px;top:883.803px;"><img id="img3_48105" src="data/images/img3.png" width="1405" height="701" alt="C:\College\Dropbox\Launchpad (2)\Seebri\PowerPoint Seebri\PPT_With_Editable_Text\popup_notrans.png" style="left:-0.164px;top:-0.189px;"/></div><div id="spr8_48105" style="left:1114px;top:1458px;"><img id="img4_48105" src="data/images/img4.png" width="969" height="66" alt="Treatments were taken once daily in the mornings between 8 AM and 11 AM and patients were tested within 1 hour of dose administration. 6"/></div><div id="spr9_48105" style="left:1108px;top:951px;"><img id="img5_48105" src="data/images/img5.png" width="1251" height="295" alt="GLOW2 (GLYCOPYRRONIUM BROMIDE IN COPD AIRWAYS-2): A 52-week treatment, randomized, double-blinded, placebo-controlled, with open-label tiotropium 18 µg, parallel-group study to assess the efficacy, safety, and tolerability of once-daily glycopyrronium 50 µg in 1066 patients (glycopyrronium n=529, open-label tiotropium n=268, placebo n=269) with chronic obstructive pulmonary disease. The primary objective was to confirm that glycopyrronium compared with placebo significantly increase mean 24-hour post-dose (trough) FEV1  following 12 weeks of treatment in patients with moderate to severe COPD. As exploratory analyses, open-label tiotropium was comapared with glycopyrronium and placebo for all study objectives.5"/></div><div id="spr10_48105" style="left:1117px;top:1300px;"><img id="img6_48105" src="data/images/img6.png" width="890" height="66" alt="For information on Seebri Breezhaler dose expression, please refer to full prescribing information."/></div><div id="spr11_48105" style="left:1727.351px;top:442.873px;"><div id="svg0_48105" style="left:0px;top:0px;"><svg width="341" height="39" viewBox="0 0 341 39"><path fill="none" d="M0,0 h340.251 v38.387 h-340.251 Z"/></svg></div><div id="spr12_48105" style="left:12.649px;top:9.127px;"><img id="img7_48105" src="data/images/img7.png" width="311" height="21" alt="Once-daily Seebri Breezhaler (n=95)1"/></div><div id="svg1_48105" style="top:45.029px;"><svg width="251" height="39" viewBox="0 0 251 39"><path fill="none" d="M0,0 h250.436 v38.387 h-250.436 Z"/></svg></div><div id="spr13_48105" style="left:12.649px;top:54.127px;"><img id="img8_48105" src="data/images/img8.png" width="137" height="21" alt="Placebo (n=95)1"/></div></div><div id="spr14_48105" style="left:2165px;top:1634px;"><img id="img9_48105" src="data/images/img9.png" width="188" height="33" alt="Study Design"/></div><div id="spr15_48105" style="left:2165px;top:1634px;"><img id="img10_48105" src="data/images/img10.png" width="188" height="33" alt="Study Design"/></div><div id="svg2_48105" style="left:2067.602px;top:1588.656px;"><svg width="387" height="121" viewBox="0 0 387 121"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h386.403 v120.049 h-386.403 Z"/></svg></div><div id="spr16_48105" style="left:392px;top:726px;"><img id="img11_48105" src="data/images/img11.png" width="32" height="483" alt="Modified Borg Dyspnea Score† (P&lt;0.05)"/></div><div id="spr17_48105" style="left:783px;top:615px;"><img id="img12_48105" src="data/images/img12.png" width="259" height="24" alt="Improvement vs placebo"/></div><div id="spr18_48105" style="left:1568px;top:700px;"><img id="img13_48105" src="data/images/img12.png" width="259" height="24" alt="Improvement vs placebo"/></div><div id="spr19_48105" style="left:1019.601px;top:1540.386px;"><img id="img14_48105" src="data/images/img13.png" width="1362" height="48" alt="C:\Work\Seebri Global Assets\137261 HTML files\popup_banner1.png" style="left:-0.169px;top:-0.237px;"/></div><div id="spr20_48105" style="left:2357.46px;top:894.324px;"><img id="img15_48105" src="data/images/img14.png" width="28" height="15" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\flyout_down_0.png" style="left:-0.248px;top:0.003px;"/></div><div id="spr21_48105" style="left:2327.055px;top:1560.294px;"><img id="img16_48105" src="data/images/img15.png" width="28" height="15" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_rapid_3_1_1_PROJECTCODE\global_seebri_en_rapid_3_1_1_PROJECTCODE\local\global_seebri_en_rapid_3_1_1_PROJECTCODE\assets\flyout_up.png" style="left:-0.248px;top:0.003px;"/></div><div id="svg3_48105" style="left:2300.752px;"><svg width="260" height="337" viewBox="0 0 260 337"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h259.248 v336.551 h-259.248 Z"/></svg></div><div id="svg4_48105" style="left:2067.602px;top:1560.294px;"><svg width="404" height="157" viewBox="0 0 404 157"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h403.276 v156.508 h-403.276 Z"/></svg></div><div id="spr22_48105" style="left:156px;top:241px;"><img id="img17_48105" src="data/images/img16.png" width="1371" height="37" alt="Significantly improved shortness of breath during exertion vs placebo at both day 1 and 214,6"/></div><div id="spr23_48105" style="top:0.26px;"><img id="img18_48105" src="data/images/img17.jpg" width="2560" height="1920" alt="C:\College\Dropbox\Launchpad (2)\Seebri\PowerPoint Seebri\3_2_2.jpg" style="top:0.24px;"/></div><div id="spr24_48105" style="top:0.26px;"><img id="img19_48105" src="data/images/img18.png" width="2560" height="1920" alt="C:\College\Dropbox\Launchpad (2)\Seebri\PowerPoint Seebri\3_2_2_chart.png" style="top:0.24px;"/></div><div id="spr25_48105" style="left:260px;top:438px;"><img id="img20_48105" src="data/images/img19.png" width="1290" height="97" alt="Significantly improved shortness of breath during exertion vs placebo at both day 1 and 214,6"/></div><div id="spr26_48105" style="left:224px;top:323px;"><img id="img21_48105" src="data/images/img20.png" width="1869" height="44" alt="In GLOW3, a 3-week trial designed to measure exercise tolerance, Seebri Breezhaler, dosed in the morning 4,6*:"/></div><div id="spr27_48105" style="left:224px;top:111px;"><img id="img22_48105" src="data/images/img21.png" width="2214" height="153" alt="MORNING WITH IMPROVED SHORTNESS OF BREATH DURING EXERTION WITH ONCE-DAILY SEEBRI ® BREEZHALER® COMPARED WITH PLACEBO4,6*"/></div><div id="spr28_48105" style="left:2014.051px;top:1245.298px;"><div id="svg5_48105" style="left:18.001px;"><svg width="430" height="126" viewBox="0 0 430 126"><path fill="none" d="M0,0 h429.373 v125.263 h-429.373 Z"/></svg></div><div id="spr29_48105" style="left:31.949px;top:17.702px;"><img id="img23_48105" src="data/images/img22.png" width="372" height="90" alt="EXERCISE TOLERANCE BACK 4,6"/></div><div id="svg6_48105" style="top:111.038px;"><svg width="483" height="47" viewBox="0 0 483 47"><path fill="none" d="M0,0 h482.022 v46.468 h-482.022 Z"/></svg></div><div id="spr30_48105" style="left:34.949px;top:124.702px;"><img id="img24_48105" src="data/images/img23.png" width="399" height="21" alt="WITH ONCE-DAILY SEEBRI BREEZHALER"/></div></div><div id="spr31_48105" style="left:1707px;top:1257px;"><img id="img25_48105" src="data/images/img24.png" width="301" height="132" alt="ADD"/></div><div id="spr32_48105" style="left:295px;top:779px;"><img id="img26_48105" src="data/images/img25.png" width="27" height="429" alt="Modified Borg Dyspnea Score† (P&lt;0.05)"/></div><div id="spr33_48105" style="left:1189px;top:1798px;"><img id="img27_48105" src="data/images/img26.png" width="493" height="34" alt="LOCAL PRESCRIBING INFORMATION"/></div><div id="spr34_48105" style="left:1232.743px;top:653.093px;"><div id="svg7_48105" style="left:0px;top:0px;"><svg width="341" height="37" viewBox="0 0 341 37"><path fill="none" d="M0,0 h340.251 v36.367 h-340.251 Z"/></svg></div><div id="spr35_48105" style="left:12.257px;top:9.907px;"><img id="img28_48105" src="data/images/img27.png" width="286" height="18" alt="Once-daily Seebri Breezhaler (n=95)1"/></div><div id="svg8_48105" style="top:32.215px;"><svg width="251" height="37" viewBox="0 0 251 37"><path fill="none" d="M0,0 h250.436 v36.367 h-250.436 Z"/></svg></div><div id="spr36_48105" style="left:12.257px;top:41.907px;"><img id="img29_48105" src="data/images/img28.png" width="126" height="18" alt="Placebo (n=95)1"/></div></div><div id="spr37_48105" style="left:1726px;top:566px;"><img id="img30_48105" src="data/images/img29.png" width="587" height="61" alt="†Borg dyspnea scale=a simple, linear 10-point scale that reproducibly measures the intensity of breathlessness."/></div><div id="spr38_48105" style="left:1727px;top:426px;"><img id="img31_48105" src="data/images/img30.png" width="516" height="56" alt="*Treatments were taken once daily in the mornings between 8 AM  and 11 AM.6"/></div><div id="spr39_48105" style="left:1726px;top:697px;"><img id="img32_48105" src="data/images/img31.png" width="587" height="61" alt="‡Borg dyspnea scale=a simple, linear 10-point scale that reproducibly measures the intensity of breathlessness."/></div><div id="spr40_48105" style="left:230.894px;top:1413.621px;"><img id="img33_48105" src="data/images/img32.png" width="1419" height="714" alt="C:\College\Dropbox\Launchpad (2)\Seebri\PowerPoint Seebri\3_2_2_popup.png" style="left:0.09px;top:0.072px;"/></div><div id="spr41_48105" style="left:1568.543px;top:1432.328px;"><img id="img34_48105" src="data/images/img15.png" width="28" height="15" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_rapid_3_1_1_PROJECTCODE\global_seebri_en_rapid_3_1_1_PROJECTCODE\local\global_seebri_en_rapid_3_1_1_PROJECTCODE\assets\flyout_up.png" style="left:-0.248px;top:0.003px;"/></div><a id="hl0_48105" href="veeva:gotoSlide(seebri_en_0_0.zip)" title="veeva:gotoSlide(seebri_en_0_0.zip)" target="_blank" onclick="return document.getElementById('coreSpr_3652585').getCore().gotoLink(this);" style="left:0px;top:1603.356px;"><div id="svg9_48105" style="left:0px;top:0px;"><svg width="543" height="318" viewBox="0 0 543 318"><path fill="#000000" fill-opacity="0" d="M0,0 h542.79 v317.644 h-542.79 Z"/></svg></div></a><a id="hl1_48105" href="veeva:gotoSlide(seebri_en_10_1_1.zip)" title="veeva:gotoSlide(seebri_en_10_1_1.zip)" target="_blank" onclick="return document.getElementById('coreSpr_3652585').getCore().gotoLink(this);" style="left:783.801px;top:1697.894px;"><div id="svg10_48105" style="left:0px;top:0px;"><svg width="327" height="224" viewBox="0 0 327 224"><path fill="#000000" fill-opacity="0" d="M0,0 h326.074 v223.106 h-326.074 Z"/></svg></div></a><a id="hl2_48105" href="veeva:gotoSlide(seebri_en_7_1_1.zip)" title="veeva:gotoSlide(seebri_en_7_1_1.zip)" target="_blank" onclick="return document.getElementById('coreSpr_3652585').getCore().gotoLink(this);" style="left:1145.318px;top:1701.985px;"><div id="svg11_48105" style="left:0px;top:0px;"><svg width="693" height="224" viewBox="0 0 693 224"><path fill="#000000" fill-opacity="0" d="M0,0 h692.316 v223.106 h-692.316 Z"/></svg></div></a><a id="hl3_48105" href="veeva:gotoSlide(seebri_en_11_0.zip)" title="veeva:gotoSlide(seebri_en_11_0.zip)" target="_blank" onclick="return document.getElementById('coreSpr_3652585').getCore().gotoLink(this);" style="left:2069.193px;top:1641.172px;"><div id="svg12_48105" style="left:0px;top:0px;"><svg width="491" height="280" viewBox="0 0 491 280"><path fill="#000000" fill-opacity="0" d="M0,0 h490.807 v279.568 h-490.807 Z"/></svg></div></a><div id="svg13_48105" style="left:1554.091px;top:341.937px;"><svg width="190" height="214" viewBox="0 0 190 214"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h189.229 v213.728 h-189.229 Z"/></svg></div><div id="spr42_48105" style="left:867px;top:1798px;"><img id="img35_48105" src="data/images/img33.png" width="184" height="33" alt="REFERENCES"/></div><div id="spr43_48105" style="left:1365px;top:1518px;"><img id="img36_48105" src="data/images/img34.png" width="188" height="33" alt="Study Design"/></div><div id="spr44_48105" style="left:1365px;top:1518px;"><img id="img37_48105" src="data/images/img35.png" width="188" height="33" alt="Study Design"/></div><div id="svg14_48105" style="left:1280px;top:1465.133px;"><svg width="369" height="129" viewBox="0 0 369 129"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h368.605 v128.769 h-368.605 Z"/></svg></div><div id="svg15_48105" style="left:1280px;top:1471.003px;"><svg width="369" height="129" viewBox="0 0 369 129"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h368.605 v128.769 h-368.605 Z"/></svg></div><div id="spr45_48105" style="left:1127px;top:832px;"><img id="img38_48105" src="data/images/img36.png" width="199" height="19" alt="Improvement vs placebo"/></div><div id="spr46_48105" style="left:584px;top:764px;"><img id="img39_48105" src="data/images/img36.png" width="199" height="19" alt="Improvement vs placebo"/></div><div id="spr47_48105" style="left:520.225px;top:911.294px;"><img id="img40_48105" src="data/images/img37.png" width="883" height="443" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\1_bars.png" style="left:-0.178px;top:-0.159px;"/></div><div id="spr48_48105" style="left:562.982px;top:871.95px;"><img id="img41_48105" src="data/images/img38.png" width="793" height="329" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\2_numbers.png" style="left:-0.185px;top:-0.057px;"/></div><div id="spr49_48105" style="left:586.587px;top:802.817px;"><img id="img42_48105" src="data/images/img39.png" width="3" height="270" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\3_1_line.png" style="left:-0.25px;top:0.056px;"/></div><div id="spr50_48105" style="left:588.685px;top:800.896px;"><img id="img43_48105" src="data/images/img40.png" width="175" height="3" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\3_2_line.png" style="left:0.014px;top:-0.249px;"/></div><div id="spr51_48105" style="left:1179px;top:1380px;"><img id="img44_48105" src="data/images/img41.png" width="80" height="28" alt="Day 21"/></div><div id="spr52_48105" style="left:640px;top:1384px;"><img id="img45_48105" src="data/images/img42.png" width="65" height="28" alt="Day 1"/></div><div id="spr53_48105" style="left:1131.59px;top:869.115px;"><img id="img46_48105" src="data/images/img39.png" width="3" height="270" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\3_1_line.png" style="left:-0.25px;top:0.056px;"/></div><div id="spr54_48105" style="left:1134.253px;top:868.843px;"><img id="img47_48105" src="data/images/img43.png" width="176" height="3" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\5_2_line.png" style="left:0.139px;top:-0.249px;"/></div><div id="spr55_48105" style="left:760.173px;top:800.746px;"><img id="img48_48105" src="data/images/img44.png" width="3" height="59" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\3_3_line.png" style="left:-0.25px;top:-0.113px;"/></div><div id="spr56_48105" style="left:1310.086px;top:871.007px;"><img id="img49_48105" src="data/images/img45.png" width="3" height="41" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\5_3_line.png" style="left:-0.248px;top:0.167px;"/></div><div id="spr57_48105" style="left:249.797px;top:772.883px;"><img id="img50_48105" src="data/images/img3.png" width="1405" height="701" alt="C:\College\Dropbox\Launchpad (2)\Seebri\PowerPoint Seebri\PPT_With_Editable_Text\popup_notrans.png" style="left:-0.164px;top:-0.189px;"/></div><div id="spr58_48105" style="left:1576.344px;top:780.878px;"><img id="img51_48105" src="data/images/img14.png" width="28" height="15" alt="C:\Work\Seebri Global Assets\137261 HTML files\137261 HTML files\SeebriHidden\global_seebri_en_improved_3_2_2_PROJECTCODE\global_seebri_en_improved_3_2_2_PROJECTCODE\local\global_seebri_en_improved_3_2_2_PROJECTCODE\assets\flyout_down_0.png" style="left:-0.248px;top:0.003px;"/></div><div id="spr59_48105" style="left:302px;top:1296px;"><img id="img52_48105" src="data/images/img46.png" width="976" height="66" alt="Treatments were taken once daily in the mornings between 8 AM and 11 AM. and patients were tested within 1 hour of dose administration. 6"/></div><div id="spr60_48105" style="left:299px;top:825px;"><img id="img53_48105" src="data/images/img47.png" width="1251" height="296" alt="GLOW2 (GLYCOPYRRONIUM BROMIDE IN COPD AIRWAYS-2): A 52-week treatment, randomized, double-blinded, placebo-controlled, with open-label tiotropium 18 µg, parallel-group study to assess the efficacy, safety, and tolerability of once-daily glycopyrronium 50 µg in 1066 patients (glycopyrronium n=529, open-label tiotropium n=268, placebo n=269) with chronic obstructive pulmonary disease. The primary objective was to confirm that glycopyrronium compared with placebo significantly increase mean 24-hour post-dose (trough) FEV1  following 12 weeks of treatment in patients with moderate to severe COPD. As exploratory analyses, open-label tiotropium was comapared with glycopyrronium and placebo for all study objectives.5"/></div><div id="spr61_48105" style="left:304px;top:1179px;"><img id="img54_48105" src="data/images/img48.png" width="890" height="67" alt="For information on Seebri Breezhaler dose expression, please refer to full prescribing information."/></div></div></div></div><div id="spr62_48105"></div><script>PlayerDemo.load('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','spr62_48105','spr63_48105',null);</script></body></html>